Fosamax and Osteonecrosis of the Jaw: Clinical Evidence Review
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health to Specific Risk: The Legacy of Fosamax and ONJ
The legacy domain of general health and science information has long provided foundational knowledge on a wide array of medical topics, including bone health and oral conditions. Within this broad context, public awareness of medication-related adverse effects has grown, particularly concerning bisphosphonate therapies such as Fosamax. Historically, discussions centered on the drug's efficacy in managing osteoporosis, with safety profiles framed in general population terms. As clinical experience accumulated, attention shifted toward specific, rare complications, notably osteonecrosis of the jaw (ONJ). This condition, characterized by exposed necrotic bone in the maxillofacial region, emerged as a significant concern in patients receiving bisphosphonate therapy. The transition from general health education to a more focused clinical evidence review involves examining the temporal relationship between Fosamax exposure and ONJ development. This pivot requires moving beyond broad health literacy to scrutinize patient-specific risk factors, including duration of therapy, dental procedures, and comorbid conditions. The occupational exposure dimension becomes relevant when considering healthcare professionals who administer or manage bisphosphonate treatments, as their clinical decision-making directly influences patient outcomes. Thus, the bridge from general health context to Fosamax exposure and ONJ risk necessitates a careful examination of clinical evidence without delving into mechanistic claims, maintaining a neutral academic tone throughout the analysis.
Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves necrotic, exposed bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Clinical presentation of ONJ typically includes exposed, non-healing bone in the jaw, often accompanied by pain, swelling, infection, and purulent discharge. Diagnosis is based on clinical examination and imaging, with a focus on ruling out metastatic disease or other causes. The condition can be debilitating, requiring surgical debridement, antibiotics, and long-term management. The time to onset of symptoms after starting Fosamax varies from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This wide range underscores the unpredictability of the adverse effect. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that the background incidence of jaw symptoms in the studied populations was not significantly elevated by the drug. However, post-marketing surveillance has identified ONJ as a distinct risk.
Mechanisms and Risk Factors for Fosamax-Associated ONJ
The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates inhibit osteoclast activity, reducing bone resorption and remodeling. In the jawbone, which has a high rate of turnover and is subject to frequent microtrauma from chewing and dental procedures, this suppression can impair the repair of microdamage and lead to avascular necrosis. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique biology of the jawbone, which may predispose it to ONJ under bisphosphonate therapy. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests a causal relationship in susceptible individuals.
Causation Considerations and Adequacy of Warnings
Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions (5.4) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label advises discontinuation if severe symptoms develop and notes the association with dental procedures and infection. However, the label also states that in placebo-controlled studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may downplay the risk. The warning does not quantify the incidence of ONJ in the general population of Fosamax users, leaving clinicians and patients without a clear risk estimate. For affected patients, causation considerations include the temporal relationship between exposure and harm, the presence of known risk factors, and the exclusion of other causes. The timeline between exposure and documented harm can range from days to months, and the risk may increase with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who develop ONJ after starting Fosamax, especially without other risk factors, may have a plausible claim of causation. In summary, Fosamax is associated with ONJ through mechanisms involving suppressed bone turnover, with risk factors including dental procedures and duration of use. The prescribing information provides a warning but may not fully convey the risk to all patients. Clinicians should consider the risk-benefit profile for each patient, particularly those with pre-existing dental conditions or planned invasive procedures.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the clinical evidence linking Fosamax to osteonecrosis of the jaw?
What are the risk factors for developing ONJ while taking Fosamax?
Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, infection). The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
How is Fosamax-associated ONJ diagnosed and managed?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.